Avacta Group Plc Change in R&D accounting policy

Hardman & Co ReportAvacta Group Plc (LON:AVCT) is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Following the Placing early in the current fiscal year to fund an in-house therapeutic Affimer programme, this has added a significant new element to the R&D spend which means that it is necessary for the company to change the method by which certain R&D investment is accounted for.

 

► Strategy: To commercialise its Affimer technology through a combination of bespoke research tools, collaborative deals and by identifying and developing its own proprietary therapeutic Affimer lead compounds. With about £20.0m on deposit, the company has the resource to deliver on its stated strategy.

► Capitalised R&D: Historically, Avacta has invested exclusively in Affimer R&D with a high probability of being embodied in commercial products, in the form of a reagent or diagnostic, in the near or medium term. Therefore, its policy has been to capitalise R&D and amortise this investment once commercialised.

► Therapeutic R&D: Following the £25m Placing earlier in fiscal 2016, Avacta has been able to execute on its strategy to develop a pipeline of therapeutic Affimers. This carries a much greater risk that a commercial product might not be achieved. Therefore, Avacta has taken the prudent view that therapeutic R&D should be written-off each year.

► Financial impact: This accounting change has no impact on cashflow. Our original forecast assumed that R&D investment of £3.8m would be capitalised. The accounting change means that £2.8m will continue to be capitalised and the £1.0m spent on therapeutic R&D will be written-off through the P&L account.

► Investment summary: Given that a putative drug in pre-clinical development has <1% probability of commercialisation, management is taking the prudent view that all its R&D investment in therapeutics should be written-off in the year in which the expenditure is incurred. This brings Avacta Group Plc in-line with normal pharmaceutical industry practice and has no effect on cashflows.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is